SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Aragon Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer